Member Login
  1. Stocks
    2. /
  2. Renalytix AI plc (LSE: RENX)
    3. /

LSE:RENX (Renalytix AI plc)

About RENX

Renalytix LSE: RENX NASDAQ: RNLX is the founder and global leader in the new field of bioprognosis for kidney health. Weve engineered a proprietary solution that successfully enables early-stage progression risk assessment when it counts the most. Renalytix. Right here until kidney disease isnt.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Renalytix AI plc (LSE: RENX) Latest News

    A pastel colored growing graph with rising rocket.
    Investing Articles

    Is Renalytix the best penny stock to buy today?

    | Zaven Boyrazian, MSc

    The Renalytix share price erupted this week as the AI diagnostics firm received a takeover bid. But is it too…

    Read more »

    Engineer Project Manager Talks With Scientist working on Computer
    Investing Articles

    After the Renalytix share price jumps 500% in 3 days, is it time to buy?

    | Alan Oscroft

    The Renalytix share price has been through a boom and bust, fuelled by AI hopes. But after the latest jump,…

    Read more »

    Female Doctor In White Coat Having Meeting With Woman Patient In Office
    Investing Articles

    Is the Renalytix share price a bargain or a falling knife?

    | Christopher Ruane

    The Renalytix share price has lost a lot of height. Could things get even worse, or is the dip a…

    Read more »

    Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
    Investing Articles

    What’s going on with the Renalytix share price?

    | Christopher Ruane

    The Renalytix share price rose sharply yesterday but has still lost 90% in a year. Christopher Ruane looks into why…

    Read more »

    Cheerful young businesspeople with laptop working in office
    Investing Articles

    Best British growth shares for July

    | The Motley Fool Staff

    We asked our freelance writers to share the top growth shares they’d buy in July, which included data firms and…

    Read more »

    Female Doctor In White Coat Having Meeting With Woman Patient In Office
    Investing Articles

    Here’s why the Renalytix share price is tanking

    | Christopher Ruane

    The Renalytix share price has lost almost 90% of its value in one year. Our writer is a shareholder --…

    Read more »

    Elevated view over city of London skyline
    Investing Articles

    2 beaten down UK growth shares to buy now with a spare £300

    | Christopher Ruane

    Our writer highlights a couple of UK growth shares with recent price falls that he would buy for his portfolio…

    Read more »

    Investing Articles

    This UK medtech share has tumbled 60%. Why would I keep buying?

    | Christopher Ruane

    After this UK medtech share lost three fifths of its value in one year, our writer assesses whether he ought…

    Read more »

    Investing Articles

    What’s going on with the Renalytix share price?

    | Christopher Ruane

    The Renalytix share price has been falling recently. Our writer considers why and explains what his next move on the…

    Read more »

    Investing Articles

    3 shares to invest in with £3,000

    | Christopher Ruane

    Christopher Ruane considers how to put £3,000 to work by setting out the investment case for a trio of shares…

    Read more »

    many happy international football fans watching tv
    Investing Articles

    Top British stocks for June

    | The Motley Fool Staff

    We asked our freelance writers to share their top British stocks for June, including Diageo, Glencore, Renalytix AI and Experian.

    Read more »

    Investing Articles

    Two UK growth shares I’m buying

    | Christopher Ruane

    In a hunt for UK growth shares, Christopher Ruane has identified two companies for his portfolio. Here he explains why…

    Read more »